Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001837607-24-000093
Filing Date
2024-11-13
Accepted
2024-11-13 16:07:36
Documents
78
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aeon-20240930x10q.htm   iXBRL 10-Q 2065094
2 EX-31 aeon-20240930xex31.htm EX-31 16221
3 EX-32 aeon-20240930xex32.htm EX-32 9207
  Complete submission text file 0001837607-24-000093.txt   9502579

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20240930.xsd EX-101.SCH 75530
5 EX-101.CAL aeon-20240930_cal.xml EX-101.CAL 42765
6 EX-101.DEF aeon-20240930_def.xml EX-101.DEF 400946
7 EX-101.LAB aeon-20240930_lab.xml EX-101.LAB 577308
8 EX-101.PRE aeon-20240930_pre.xml EX-101.PRE 533939
81 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240930x10q_htm.xml XML 1662521
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40021 | Film No.: 241454162
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)